{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:48:50Z","timestamp":1791910130713,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":111,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"DOI":"10.1038\/s41523-026-00982-5","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:47:35Z","timestamp":1782287255000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anlotinib-containing regimens in HR+ advanced breast cancer after prior CDK4\/6 inhibitor progression"],"prefix":"10.1038","volume":"12","author":[{"given":"Yifei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binliang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quchang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"982_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1470-2045(00)00254-0","volume":"2","author":"TJ Key","year":"2001","unstructured":"Key, T. J., Verkasalo, P. K. & Banks, E. Epidemiology of breast cancer. Lancet Oncol. 2, 133\u2013140 (2001).","journal-title":"Lancet Oncol."},{"key":"982_CR2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","volume":"62","author":"CK Osborne","year":"2011","unstructured":"Osborne, C. K. & Schiff, R. Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med. 62, 233\u2013247 (2011).","journal-title":"Annu. Rev. Med."},{"key":"982_CR3","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ctrv.2018.07.013","volume":"69","author":"J O\u2019Shaughnessy","year":"2018","unstructured":"O\u2019Shaughnessy, J., Thaddeus Beck, J. & Royce, M. Everolimus-based combination therapies for HR+, HER2\u2212 metastatic breast cancer. Cancer Treat. Rev. 69, 204\u2013214 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"982_CR4","doi-asserted-by":"publisher","first-page":"e13035","DOI":"10.1200\/JCO.2021.39.15_suppl.e13035","volume":"39","author":"IV Kolyadina","year":"2021","unstructured":"Kolyadina, I. V. et al. The effectiveness and safety of eribulin therapy in HR-positive HER2-negative metastatic breast cancer post-CDK4\/6 inhibitor therapy in Russian clinical practice. J. Clin. Oncol. 39, e13035 (2021).","journal-title":"J. Clin. Oncol."},{"key":"982_CR5","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","volume":"25","author":"M Piccart","year":"2014","unstructured":"Piccart, M. et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann. Oncol. 25, 2357\u20132362 (2014).","journal-title":"Ann. Oncol."},{"key":"982_CR6","doi-asserted-by":"publisher","first-page":"101103","DOI":"10.1016\/j.drup.2024.101103","volume":"76","author":"A Glaviano","year":"2024","unstructured":"Glaviano, A. et al. Mechanisms of sensitivity and resistance to CDK4\/CDK6 inhibitors in hormone receptor-positive breast cancer treatment. Drug Resistance Updates 76, 101103 (2024).","journal-title":"Drug Resistance Updates"},{"key":"982_CR7","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1172\/JCI137552","volume":"130","author":"EC de Heer","year":"2020","unstructured":"de Heer, E. C., Jalving, M. & Harris, A. L. HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer. J. Clin. Investig. 130, 5074\u20135087 (2020).","journal-title":"J. Clin. Investig."},{"key":"982_CR8","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","volume":"77","author":"R Lugano","year":"2020","unstructured":"Lugano, R., Ramachandran, M. & Dimberg, A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell. Mol. Life Sci. 77, 1745\u20131770 (2020).","journal-title":"Cell. Mol. Life Sci."},{"key":"982_CR9","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","volume":"29","author":"NJ Robert","year":"2011","unstructured":"Robert, N. J. et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2\u2013negative, locally recurrent or metastatic breast cancer. J. Clin. Oncol. 29, 1252\u20131260 (2011).","journal-title":"J. Clin. Oncol."},{"key":"982_CR10","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/annonc\/mdu438.5","volume":"25","author":"J Baselga","year":"2014","unstructured":"Baselga, J. et al. LBA8 - a phase III randomized, double-blind, trial comparing sorafenib plus capecitabine versus placebo plus capecitabine in the treatment of locally advanced or metastatic Her2-negative breast cancer (Resilience). Ann. Oncol. 25, v1 (2014).","journal-title":"Ann. Oncol."},{"key":"982_CR11","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1200\/JCO.2011.35.7376","volume":"30","author":"J Bergh","year":"2012","unstructured":"Bergh, J. et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J. Clin. Oncol. 30, 921\u2013929 (2012).","journal-title":"J. Clin. Oncol."},{"key":"982_CR12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","volume":"11","author":"G Shen","year":"2018","unstructured":"Shen, G. et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J. Hematol. Oncol. 11, 120 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"982_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0718-5","volume":"12","author":"S Qin","year":"2019","unstructured":"Qin, S. et al. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J. Hematol. Oncol. 12, 1\u201311 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"982_CR14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3892\/ijmm.2022.5184","volume":"50","author":"J Huang","year":"2022","unstructured":"Huang, J., Zheng, L., Sun, Z. & Li, J. CDK4\/6 inhibitor resistance mechanisms and treatment strategies. Int. J. Mol. Med. 50, 128 (2022).","journal-title":"Int. J. Mol. Med."},{"key":"982_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","volume":"654","author":"B Lin","year":"2018","unstructured":"Lin, B. et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFR\u03b2 and FGFR1. Gene 654, 77\u201386 (2018).","journal-title":"Gene"},{"key":"982_CR16","doi-asserted-by":"publisher","first-page":"5396107","DOI":"10.1155\/2024\/5396107","volume":"2024","author":"T Xu","year":"2024","unstructured":"Xu, T., Xiong, W., Zhang, L. & Yuan, Y. The effects of anlotinib combined with chemotherapy following progression on cyclin-dependent kinase 4\/6 inhibitor in hormone receptor-positive metastatic breast cancer. Breast J. 2024, 5396107 (2024).","journal-title":"Breast J."},{"key":"982_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-13403-2","volume":"25","author":"J Liu","year":"2025","unstructured":"Liu, J. et al. Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study. BMC Cancer 25, 9 (2025).","journal-title":"BMC Cancer"},{"key":"982_CR18","doi-asserted-by":"publisher","first-page":"849","DOI":"10.20892\/j.issn.2095-3941.2020.0463","volume":"18","author":"N Hu","year":"2021","unstructured":"Hu, N. et al. Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer. Cancer Biol. Med. 18, 849\u2013859 (2021).","journal-title":"Cancer Biol. Med."},{"key":"982_CR19","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3389\/fonc.2022.1042451","volume":"12","author":"Y Qian","year":"2022","unstructured":"Qian, Y., Lou, K., Zhou, H., Zhang, L. & Yuan, Y. Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients. Front. Oncol. 12, 2022 (2022).","journal-title":"Front. Oncol."},{"key":"982_CR20","doi-asserted-by":"publisher","first-page":"101563","DOI":"10.1016\/j.esmoop.2023.101563","volume":"8","author":"B Liu","year":"2023","unstructured":"Liu, B. et al. A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer. ESMO Open 8, 101563 (2023).","journal-title":"ESMO Open"},{"key":"982_CR21","doi-asserted-by":"publisher","first-page":"175883592110228","DOI":"10.1177\/17588359211022890","volume":"13","author":"Y Li","year":"2021","unstructured":"Li, Y. et al. A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+\/HER2\u2212 metastatic breast cancer. Therapeutic Adv. Med. Oncol. 13, 17588359211022890 (2021).","journal-title":"Therapeutic Adv. Med. Oncol."},{"key":"982_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.6004\/jnccn.2018.7094","volume":"17","author":"J Xi","year":"2019","unstructured":"Xi, J. et al. Retrospective analysis of treatment patterns and effectiveness of palbociclib and subsequent regimens in metastatic breast cancer. J. Natl. Compr. Cancer Netw. 17, 141\u2013147 (2019).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"982_CR23","first-page":"117822342094486","volume":"14","author":"A Dhakal","year":"2020","unstructured":"Dhakal, A. et al. Outcome of everolimus-based therapy in hormone-receptor-positive metastatic breast cancer patients after progression on palbociclib. Breast Cancer: Basic Clin. Res. 14, 1178223420944864 (2020).","journal-title":"Breast Cancer: Basic Clin. Res."},{"key":"982_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.breast.2022.10.018","volume":"66","author":"J Zhou","year":"2022","unstructured":"Zhou, J. et al. Clinical outcomes of tucidinostat-based therapy after prior CDK4\/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer. Breast 66, 255\u2013261 (2022).","journal-title":"Breast"},{"key":"982_CR25","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/JCO.22.02392","volume":"41","author":"K Kalinsky","year":"2023","unstructured":"Kalinsky, K. et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 inhibition in hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative metastatic breast cancer: MAINTAIN trial. J. Clin. Oncol. 41, 4004\u20134013 (2023).","journal-title":"J. Clin. Oncol."},{"key":"982_CR26","doi-asserted-by":"publisher","first-page":"e629","DOI":"10.1016\/S1470-2045(24)00673-9","volume":"25","author":"HS Rugo","year":"2024","unstructured":"Rugo, H. S. et al. Alpelisib plus fulvestrant in <em>PIK3CA<\/em>-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 25, e629\u2013e638 (2024).","journal-title":"Lancet Oncol."},{"key":"982_CR27","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","volume":"392","author":"KL Jhaveri","year":"2025","unstructured":"Jhaveri, K. L. et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N. Engl. J. Med. 392, 1189\u20131202 (2025).","journal-title":"N. Engl. J. Med."},{"key":"982_CR28","doi-asserted-by":"publisher","first-page":"S1561","DOI":"10.1016\/j.annonc.2025.09.026","volume":"36","author":"E Mayer","year":"2025","unstructured":"Mayer, E. et al. LBA16 Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2\u2013 aBC) previously treated with a CDK4\/6 inhibitor (i): Primary results of the phase III evERA BC trial. Annals Oncol. 36, S1561\u2013S1562 (2025).","journal-title":"Annals Oncol."},{"key":"982_CR29","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1200\/JCO.22.01002","volume":"40","author":"HS Rugo","year":"2022","unstructured":"Rugo, H. S. et al. Sacituzumab govitecan in hormone receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative metastatic breast cancer. J. Clin. Oncol. 40, 3365\u20133376 (2022).","journal-title":"J. Clin. Oncol."},{"key":"982_CR30","unstructured":"Komal Jhaveri, Y. H. P., et al. Sacituzumab govitecan vs physician\u2019s choice chemotherapy as first-line chemotherapy after endocrine therapy in HR+\/HER2\u2212 metastatic breast cancer: results from the ASCENT-07 trial. https:\/\/sabcs.org\/."},{"key":"982_CR31","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.annonc.2023.07.004","volume":"34","author":"T Wei","year":"2023","unstructured":"Wei, T., Wang, D. & Yuan, P. The role of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment. Ann. Oncol. 34, 948\u2013949 (2023).","journal-title":"Ann. Oncol."},{"key":"982_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med. 387, 9\u201320 (2022).","journal-title":"N. Engl. J. Med."},{"key":"982_CR33","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1200\/JCO.2009.25.9796","volume":"28","author":"MA Schonberg","year":"2010","unstructured":"Schonberg, M. A. et al. Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. J. Clin. Oncol. 28, 2038\u20132045 (2010).","journal-title":"J. Clin. Oncol."},{"key":"982_CR34","doi-asserted-by":"crossref","unstructured":"Anjali, V. R. Breast Cancer in Elderly Female. In: Mallick S., Sharma C. K., eds. Evidence in Breast Cancer. Springer Nature Singapore; 2024:381\u2013389.","DOI":"10.1007\/978-981-97-7755-6_33"},{"key":"982_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2009.11.003","volume":"292","author":"Y Zhang","year":"2010","unstructured":"Zhang, Y., Ma, B. & Fan, Q. Mechanisms of breast cancer bone metastasis. Cancer Lett. 292, 1\u20137 (2010).","journal-title":"Cancer Lett."},{"key":"982_CR36","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/cells10061377","volume":"10","author":"K Venetis","year":"2021","unstructured":"Venetis, K. et al. Breast cancer with bone metastasis: molecular insights and clinical management. Cells 10, 1377 (2021).","journal-title":"Cells"},{"key":"982_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-018-0054-x","volume":"4","author":"A Parkes","year":"2018","unstructured":"Parkes, A. et al. Characterization of bone only metastasis patients with respect to tumor subtypes. NPJ Breast Cancer 4, 2 (2018).","journal-title":"NPJ Breast Cancer"},{"key":"982_CR38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40164-015-0023-0","volume":"4","author":"J Xie","year":"2015","unstructured":"Xie, J. et al. Clinical outcomes among HR+\/HER2\u2212 metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US. Exp. Hematol. Oncol. 4, 31 (2015).","journal-title":"Exp. Hematol. Oncol."},{"key":"982_CR39","doi-asserted-by":"publisher","first-page":"100332","DOI":"10.1016\/j.esmoop.2021.100332","volume":"6","author":"E Munzone","year":"2021","unstructured":"Munzone, E. et al. Systematic review and meta-analysis of post-progression outcomes in ER+\/HER2\u2212 metastatic breast cancer after CDK4\/6 inhibitors within randomized clinical trials. ESMO Open 6, 100332 (2021).","journal-title":"ESMO Open"},{"key":"982_CR40","doi-asserted-by":"publisher","first-page":"GS3-04","DOI":"10.1158\/1538-7445.SABCS22-GS3-04","volume":"83","author":"N Turner","year":"2023","unstructured":"Turner, N. et al. Abstract GS3-04: GS3-04 Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial. Cancer Res. 83, GS3-04\u2013GS03-04 (2023).","journal-title":"Cancer Res."},{"key":"982_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/onco.13609","volume":"26","author":"MM Cook","year":"2020","unstructured":"Cook, M. M. et al. Everolimus plus exemestane treatment in patients with metastatic hormone receptor-positive breast cancer previously treated with CDK4\/6 inhibitor therapy. Oncologist 26, 101\u2013106 (2020).","journal-title":"Oncologist"},{"key":"982_CR42","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1200\/JCO-24-02086","volume":"43","author":"K Kalinsky","year":"2025","unstructured":"Kalinsky, K. et al. Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 inhibition: results from the phase III postMONARCH trial. J. Clin. Oncol. 43, 1101\u20131112 (2025).","journal-title":"J. Clin. Oncol."},{"key":"982_CR43","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"F-C Bidard","year":"2022","unstructured":"Bidard, F.-C. et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor\u2013Positive, Human Epidermal Growth Factor Receptor 2\u2013Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J. Clin. Oncol. 40, 3246\u20133256 (2022).","journal-title":"J. Clin. Oncol."}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00982-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00982-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00982-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:04:42Z","timestamp":1791907482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00982-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["982"],"URL":"https:\/\/doi.org\/10.1038\/s41523-026-00982-5","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"131"}}